Co-Authors
This is a "connection" page, showing publications co-authored by PHILIP LUPO and RAJKUMAR VENKATRAMANI.
Connection Strength
1.555
-
The impact of genetic ancestry on survival outcomes in pediatric rhabdomyosarcoma: A report from the Children's Oncology Group. HGG Adv. 2025 Jul 10; 6(3):100466.
Score: 0.243
-
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. JCO Precis Oncol. 2025 Feb; 9:e2400556.
Score: 0.238
-
Improving Individualized Rhabdomyosarcoma Prognosis Predictions Using Somatic Molecular Biomarkers. medRxiv. 2024 Sep 05.
Score: 0.231
-
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024 03 04; 7(3):e244170.
Score: 0.223
-
Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group. J Natl Cancer Inst. 2023 06 08; 115(6):733-741.
Score: 0.212
-
Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001-2017. Cancer Med. 2023 02; 12(3):3644-3656.
Score: 0.201
-
TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report. Pediatr Blood Cancer. 2023 May 17; e30413.
Score: 0.053
-
Impact of race and ethnicity on presentation and outcomes of patients treated on rhabdomyosarcoma clinical trials: A report from the Children's Oncology Group. Cancer Med. 2023 06; 12(11):12777-12791.
Score: 0.052
-
Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis. Cancer Med. 2023 05; 12(9):10222-10229.
Score: 0.052
-
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur J Cancer. 2022 09; 172:367-386.
Score: 0.050